What is the treatment of choice for a hepatitis B surface antigen (HBsAg) positive patient with hepatocellular carcinoma?

Treatment of HBsAg-Positive HCC Patients

For HBsAg-positive patients with hepatocellular carcinoma, surgical resection or liver transplantation remains the treatment of choice for curative intent, with mandatory concurrent antiviral therapy using nucleoside/nucleotide analogues to prevent HBV reactivation and improve outcomes 1.

Treatment Algorithm Based on Tumor Stage and Liver Function

Early-Stage Disease (Single tumor ≤5 cm or 2-3 tumors ≤3 cm)

Child-Pugh Class A:

• Surgical resection is the primary option for patients with preserved liver function and no significant portal hypertension 1
• Liver transplantation should be considered for patients meeting Milan criteria (single tumor ≤5 cm or up to 3 tumors ≤3 cm), particularly those with underlying cirrhosis 1, 2
• Percutaneous ablation (radiofrequency ablation or ethanol injection) for peripheral lesions <3 cm when surgery is not feasible 1

Child-Pugh Class B:

• Liver transplantation is the preferred option 3, 1
• Percutaneous techniques or transarterial chemoembolization (TACE) as bridging therapy while awaiting transplant 2

Child-Pugh Class C:

• Liver transplantation only if eligible; otherwise, best supportive care 3, 4

Intermediate-Stage Disease (Multifocal without vascular invasion)

Child-Pugh A/B:

• TACE is the standard palliative treatment for multifocal disease with preserved liver function 1, 4
• Consider surgical resection for peripheral tumors if technically feasible 3

Advanced Disease (Vascular invasion or metastases)

• Sorafenib or other systemic therapies (lenvatinib, atezolizumab-bevacizumab combinations) 4, 5
• Systemic chemotherapy has poor response rates and should only be offered in clinical trials 1

Critical HBV-Specific Considerations

Mandatory Antiviral Therapy

All HBsAg-positive HCC patients must receive nucleoside/nucleotide analogue therapy 6, 7. This is non-negotiable because:

• HBV reactivation occurs in 19-32% of patients undergoing TACE without prophylaxis 8
• Absence of prophylactic antiviral therapy increases HBV reactivation risk 3.56-fold 8
• HBV reactivation independently predicts poor overall survival (HR 1.43) 8
• Antiviral therapy reduces tumor recurrence, reverses liver fibrosis, and extends survival 7

Timing: Start antiviral therapy before or at the time of any HCC treatment and continue indefinitely 6, 7.

Impact on Transplantation

Historically, patients with replicating HBV had worse outcomes post-transplant due to HBV recurrence and were not considered transplant candidates. However, with effective antiviral therapy now available, HBsAg-positive patients with small HCC should be assessed for transplantation 1. The combination of antiviral therapy and hepatitis B immunoglobulin post-transplant prevents HBV recurrence 9.

Common Pitfalls to Avoid

1. Never perform HCC treatment without concurrent antiviral therapy - this is the single most important modifiable risk factor for poor outcomes in HBsAg-positive patients 8, 7

2. Do not assume HBsAg seroclearance eliminates HCC risk - patients who clear HBsAg, especially those with cirrhosis or age ≥50 years, still require HCC surveillance as annual incidence remains 0.43-0.62% 10, 11

3. Avoid biopsy of potentially resectable lesions - needle tract seeding occurs in 1-3% of cases 1

4. Do not use tamoxifen - hormonal therapy shows no survival benefit in controlled trials 1

5. Avoid resection in Child-Pugh B/C without transplant backup - high risk of postoperative hepatic decompensation 1

Nuances in HBV-Related HCC

The evidence consistently shows that HBsAg itself may have direct oncogenic effects independent of cirrhosis, as HBV-related HCC can occur without cirrhosis 9. High preoperative HBsAg levels (>1000 IU/mL) predict worse recurrence-free survival, and postoperative antiviral therapy shows more significant benefits in patients with lower preoperative HBsAg levels 12.

Recent data suggests that combining locoregional therapy (DEB-TACE) with systemic therapy (lenvatinib plus immune checkpoint inhibitors) may achieve complete response and even HBsAg clearance in advanced HCC with portal vein invasion 5, though this requires validation in larger studies.

Follow-Up Protocol

Post-treatment surveillance every 3-6 months with:

• AFP measurement
• Liver imaging (CT or MRI)
• HBV DNA monitoring
• Liver function tests

Continue for at least 2 years, as curative therapy can still be offered for early recurrence 4, 2.